<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
<journal-title>Frontiers in Oncology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Oncol.</abbrev-journal-title>
<issn pub-type="epub">2234-943X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fonc.2023.1128278</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Oncology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>A novel 25-ferroptosis-related gene signature for the prognosis of gliomas</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Peng</surname>
<given-names>Xiaojiang</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Chun</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Jing</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2113323"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bao</surname>
<given-names>Zeqing</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Tao</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zeng</surname>
<given-names>Lingfeng</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>He</surname>
<given-names>Qixiong</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Xue</surname>
<given-names>Daojin</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2142102"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Zhaoqing Medical College</institution>, <addr-line>Zhaoqing</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Neurosurgery, Lianshui People&#x2019;s Hospital Affiliated to Kangda College of Nanjing Medical University</institution>, <addr-line>Huaian</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Department of Neurosurgery, The First Affiliated Hospital of Chongqing Medical University</institution>, <addr-line>Chongqing</addr-line>, <country>China</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Department of Neurosurgery, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Department of Medicine, Chinese University of Hong Kong</institution>, <addr-line>Hong Kong</addr-line>, <country>Hong Kong SAR, China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Qing Li, Daping Hospital, China</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Hanlin Yang, Guizhou Provincial People's Hospital, China; Wei Zhang, Sichuan Cancer Hospital, China</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Daojin Xue, <email xlink:href="mailto:daojinmed@outlook.com">daojinmed@outlook.com</email>
</p>
</fn>
<fn fn-type="equal" id="fn003">
<p>&#x2020;These authors have contributed equally to this work</p>
</fn>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>20</day>
<month>04</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>13</volume>
<elocation-id>1128278</elocation-id>
<history>
<date date-type="received">
<day>20</day>
<month>12</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>30</day>
<month>03</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Peng, Liu, Li, Bao, Huang, Zeng, He and Xue</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Peng, Liu, Li, Bao, Huang, Zeng, He and Xue</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>Ferroptosis is closely associated with cancer and is of great importance in the immune evasion of cancer. However, the relationship between ferroptosis and glioma is unclear.</p>
</sec>
<sec>
<title>Methods</title>
<p>We downloaded the expression profiles and clinical data of glioma from the GlioVis database and obtained the expression profiles of ferroptosis genes. A ferroptosis-related gene signature was developed for the prognosis of gliomas.</p>
</sec>
<sec>
<title>Results</title>
<p>We screened out prognostic ferroptosis genes, named ferroptosis-related genes, by the Cox regression method. Based on these genes, we used unsupervised clustering to obtain two different clusters; the principal component analysis algorithm was applied to determine the gene score of each patient, and then all the patients were classified into two subgroups. Results showed that there exist obvious differences in survival between different clusters and different gene score subgroups. The prognostic model constructed by the 25 ferroptosis-related genes was then evaluated to predict the clinicopathological features of immune activity in gliomas.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>The ferroptosis-related genes play an important role in the malignant process of gliomas, potentially contributing to the development of prognostic stratification and treatment strategies.</p>
</sec>
</abstract>
<kwd-group>
<kwd>ferroptosis</kwd>
<kwd>gene signature</kwd>
<kwd>prognosis</kwd>
<kwd>gliomas</kwd>
<kwd>bioinformatic</kwd>
</kwd-group>
<counts>
<fig-count count="5"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="39"/>
<page-count count="8"/>
<word-count count="3126"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Glioma (GBM) is a kind of brain tumor, with an incidence of 5&#x2013;6 cases per 100,000 people (<xref ref-type="bibr" rid="B1">1</xref>&#x2013;<xref ref-type="bibr" rid="B3">3</xref>). Malignant glioma is a kind of highly invasive tumor, accounting for approximately 55% of gliomas, with a median survival period of 14-16 months (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>). Glioma has strong heterogeneity, which always leads to an increased recurrence rate after curative treatment (<xref ref-type="bibr" rid="B6">6</xref>). Despite aggressive treatments, the prognosis of malignant glioma is still poor. Hence, it is urgent to develop new therapeutic methods to enhance the prognosis of patients with glioma. Many scholars found that tumor cells have characteristics different from the cells of normal tissue, such as the avoidance of cell death (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>). The tumor microenvironment (TME) is considered a crucial factor in regulating invasion and preventing the destruction and survival of blood vessels (<xref ref-type="bibr" rid="B9">9</xref>&#x2013;<xref ref-type="bibr" rid="B11">11</xref>). Glioma cells utilize their TME to maintain cellular homeostasis to avoid or reduce cell death (<xref ref-type="bibr" rid="B12">12</xref>). Regulated cell death (RCD) refers to death associated with gene regulation originating from the extracellular microenvironment which is essential to restore cellular homeostasis (<xref ref-type="bibr" rid="B13">13</xref>).</p>
<p>Ferroptosis, a newly discovered non-apoptotic RCD (<xref ref-type="bibr" rid="B14">14</xref>), is mediated by the accumulation of reactive oxygen species (ROS). In essence, under the action of ferroptosis, the accumulation of lipid peroxides leads to an imbalance in intracellular redox, leading to ferroptosis (<xref ref-type="bibr" rid="B15">15</xref>). Inhibition of glutathione peroxidase 4 (GPX4) or glutathione synthesis by small molecular compounds has been shown to result in ferroptosis (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>). Ferroptosis is associated with various diseases, such as ischemia&#x2013;reperfusion injury, neurodegenerative diseases, and tumors. Several studies have shown that ferroptosis is a key factor in acquired drug resistance and immune evasion of cancer (<xref ref-type="bibr" rid="B18">18</xref>). In glioma, autophagy inhibition can improve the sensitivity of glioma stem cells to temozolomide (TMZ) by causing ferroptosis (<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B20">20</xref>). However, there are few reports on how ferroptosis occurs, develops, affects, and regulates glioma. It is important to study the biological significance of ferroptosis-related genes in glioma so as to construct a novel treatment method.</p>
<p>Recently, many researchers have been inclined to use bioinformatics methods to study the genesis and development mechanism of tumors. Using bioinformatics methods, we can determine the most appropriate samples for testing and identify the pathways and genes that can affect the development of glioma more quickly and accurately, thus providing more ideas for the treatment of glioma and the prediction of patient&#x2019;s prognosis.</p>
</sec>
<sec id="s2" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="s2_1">
<title>Data source</title>
<p>Gene expression data and the glioma patient survival information in The Cancer Genome Atlas (TCGA) program were downloaded from the GlioVis GBM platform (<ext-link ext-link-type="uri" xlink:href="http://gliovis.bioinfo.cnio.es/">http://gliovis.bioinfo.cnio.es/</ext-link>) (<xref ref-type="bibr" rid="B21">21</xref>), in which the RNA-seq data were processed by the normalized read counts from the preprocessed data with log2 transformation.</p>
</sec>
<sec id="s2_2">
<title>Prognostic ferroptosis gene identification and prediction and PCA score calculation</title>
<p>We downloaded 253 ferroptosis regulators, 111 ferroptosis markers, and 95 ferroptosis&#x2013;disease associations from FerrDb (<ext-link ext-link-type="uri" xlink:href="http://www.zhounan.org/ferrdb">http://www.zhounan.org/ferrdb</ext-link>). FerrDb can be used to obtain insights into ferroptosis (<xref ref-type="fig" rid="f1">
<bold>Figure 1A</bold>
</xref>) (<xref ref-type="bibr" rid="B22">22</xref>). The ferroptosis gene expression data in the TCGA-GBM were obtained, and the ferroptosis genes significantly correlated with prognosis were determined based on the Cox regression method (<italic>p</italic>-value &lt; 0.05). The expression matrix of relevant iron metabolism genes was extracted. Then, the score of each TCGA-GBM sample was calculated according to the principal component analysis (PCA) algorithm. PCA was applied to establish a ferroptosis-relevant score model, namely, the PCA score, and the PCA score was determined based on the formula: PCA score = (PC1<italic>i</italic> + PC2<italic>i</italic>), in which <italic>i</italic> represents the level of ferroptosis family pattern-related signature genes. Both PC1 and PC2 were regarded as signature scores. According to the threshold, the patients were classified into high- and low-score groups, while the relevant survival curves were generated and checked by the log-rank test between the two groups.</p>
</sec>
<sec id="s2_3">
<title>Identification of differentially expressed ferroptosis-related genes</title>
<p>We identified the differentially expressed genes (DEGs) between the high-score and low-score groups. The &#x201c;limma&#x201d; package (<xref ref-type="bibr" rid="B23">23</xref>) of R was used to identify DEGs. Fold-change (FC) &gt;1 and adjusted <italic>p</italic>-value &lt;0.05 were set as the judgment standard for DEGs. An adjusted <italic>p</italic>-value &lt;0.05 was applied to control the false-positive rate (<xref ref-type="bibr" rid="B24">24</xref>).</p>
</sec>
<sec id="s2_4">
<title>Identification of the ferroptosis-related gene cluster in the TCGA-GBM</title>
<p>Based on the screened DEGs, unsupervised clustering was applied to cluster distant genotypes of the TCGA-GBM samples by the &#x201c;ConsensusClusterPlus&#x201d; package (<xref ref-type="bibr" rid="B25">25</xref>). Heatmaps were drawn to visualize the clinical characteristics of different gene clusters. The GBM score of each individual was also determined by these ferroptosis-associated DEGs, which we called the PCA gene score. In terms of cutoff value, the cases were classified into the high-gene score and low-gene score groups. Kaplan&#x2013;Meier (KM) curves were generated and compared with the log-rank test between the high-gene score and low-gene score groups.</p>
</sec>
<sec id="s2_5">
<title>Functional enrichment analysis</title>
<p>Gene ontology (GO) analysis (<xref ref-type="bibr" rid="B26">26</xref>) was used to analyze the function of the gene products and to identify their biological feature. The Kyoto Encyclopedia of Genes and Genomes (KEGG) (<xref ref-type="bibr" rid="B27">27</xref>) enrichment analysis was mainly used to explain gene function and was widely used in the bioinformatics research field. Based on DEG, it was mainly applied to the &#x201c;ClusterProfiler&#x201d; software (<xref ref-type="bibr" rid="B28">28</xref>) during the GO and KEGG analyses. The &#x201c;gsva&#x201d; package (<xref ref-type="bibr" rid="B29">29</xref>) was mainly used for single-sample gene set enrichment analysis (ssGSEA) to determine the proportion of infiltrating immune cells and also to determine the activity difference of immune pathways in different groups. The correlations of infiltrating immune cells and PCA score/gene score were shown in correlation heatmaps.</p>
</sec>
<sec id="s2_6">
<title>Western blotting</title>
<p>The milled tissue and cells were lysed and boiled in sodium dodecyl sulfate (SDS) sample loading buffer, separated by 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to PVDF membranes. The membranes were blocked in 5% skimmed milk for 1&#xa0;h, washed three times with TBST, incubated with the appropriate primary antibody in TBST for 1&#xa0;h, then washed twice, and incubated with horseradish peroxide-conjugated anti-immunoglobulin (1:5,000 dilution) for 1&#xa0;h at room temperature. After three washes with TBST, the membranes were developed using ECL-enhanced chemiluminescence reagents.</p>
</sec>
<sec id="s2_7">
<title>Immunohistochemistry</title>
<p>Tissues were fixed in 4% paraformaldehyde for 24&#xa0;h, followed by embedding in paraffin. Sections were cut to a thickness of 5 &#x3bc;m and incubated with anti-MAP1LC3A, anti-OLFM1, anti-CEND1, anti-CLTB, anti-PRKAR1B, anti-HRAS, anti-DDRGK1, anti-PITHD1, and anti-DEAF1 primary antibodies. Hematoxylin restaining was followed by separate photographic observation of each slide in a positive area of &#xd7;40 fields, which were independently analyzed by three previously uninformed pathologists.</p>
</sec>
<sec id="s2_8">
<title>Statistical analysis</title>
<p>To compare the overall survival (OS) of the subgroups, the KM curve with the log-rank test was applied (<xref ref-type="bibr" rid="B30">30</xref>). In order to determine the prognostic value of the iron production death gene in the research process, this paper conducted Cox regression analysis on the collected data and applied the Mann&#x2013;Whitney method when comparing the degree of immune cell infiltration of the two groups. The correlations of infiltrating immune cells and PCA score/gene score were established using the Pearson correlation coefficient. The statistical analyses were carried out based on R (version 4.0.5).</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<title>Results</title>
<sec id="s3_1">
<title>Ferroptosis genes were correlated with prognosis in human GBMs</title>
<p>Using univariate regression analysis, we screened 14 ferroptosis genes associated with OS in patients with GBM. According to the optimal threshold of the level of these genes in the TCGA-GBM, the cases were divided into two groups with high and low expression. The KM curve showed significant prognostic differences between the high and low gene expression groups (<italic>p</italic>-value &lt; 0.05). The PCA algorithm was applied to determine the PCA score of each TCGA-GBM individual based on these 14 genes. The results showed that a high score has a positive relationship with prognosis (<italic>p</italic> = 0.002, <xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1B</bold>
</xref>).</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>
<bold>(A)</bold> Research flow chart. <bold>(B)</bold> Kaplan&#x2013;Meier curves of the principal component analysis (PCA) scores in the TCGA-GBM.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1128278-g001.tif"/>
</fig>
</sec>
<sec id="s3_2">
<title>Identification of DEGs between the high-score and low-score groups</title>
<p>Up to 231 DEGs were identified, among which 183 were upregulated and 48 were downregulated in the high-score group. To further explore the biological role of these ferroptosis-related genes in GBM, we performed GO and KEGG analyses on these DEGs. The GO result reflected that the GO annotations of DEGs can be classified into three categories: biological processes (BPs), cell components (CCs), and molecular functions (MFs). The terms were arranged based on the false discovery rate (FDR) value, and further screening was performed when FDR &lt;0.05. Screening showed that the DEGs were enriched in processes of regulation of long-term neuronal synaptic plasticity, proteasome-mediated ubiquitin-dependent protein degradation, vesicle-mediated transport in synapses, and proteasomal protein catabolic processes (<xref ref-type="supplementary-material" rid="SM1">
<bold>Figures S1A, B</bold>
</xref>). The signal pathway results were ranked based on FDR value and were screened under the condition of FDR &lt;0.05. The KEGG result reflected that the DEGs were mainly enriched in endocytosis, Alzheimer&#x2019;s disease, and pathways of neurodegeneration in multiple diseases (<xref ref-type="supplementary-material" rid="SM1">
<bold>Figures S1C, D</bold>
</xref>).</p>
</sec>
<sec id="s3_3">
<title>Tumor ferroptosis-related classification according to the identified DEGs</title>
<p>To study the association of the expression level and GBM subtypes of the 231 ferroptosis-related DEGs, we conducted univariate Cox regression and consensus clustering test with all GBM cases in the TCGA. When the clustering variable (<italic>k</italic>) increased from 2 to 10, it can be found that when <italic>k</italic> = 2, there appeared the highest intragroup associations and the lowest intergroup associations, which reflected that the 158 GBM cases can be perfectly divided into two groups by the 25 prognostic DEGs (<xref ref-type="fig" rid="f2">
<bold>Figures&#xa0;2A&#x2013;D</bold>
</xref>). The clinical features, such as PCA score (high score or low score), sex (male or female), age (&#x2264;65 or &gt;65 years), and survival condition, were listed in a heatmap (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3A</bold>
</xref>), and a few differences in sex and age between the two groups were found. The OS rates were also compared, and we found significant differences (<italic>p</italic> = 0.013, <xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3B</bold>
</xref>). To study the prognostic effects of these genes, the PCA algorithm was also applied to determine the PCA gene score of each individual, and cases were divided into two groups. The KM curves showed that the high-score group had obviously a better prognosis (<italic>p</italic> &lt; 0.001, <xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3C</bold>
</xref>).</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Identification of GBM ferroptosis-related subgroups. <bold>(A, B)</bold> Heatmap of the samples under the condition of consensus <italic>k</italic> = 2 <bold>(A)</bold> and <italic>k</italic> = 3 <bold>(B)</bold>. <bold>(C)</bold> Consensus clustering cumulative distribution function (CDF) for <italic>k</italic> = 2 to 9. <bold>(D)</bold> Relative change in the area under the CDF curve for <italic>k</italic> = 2 to 9.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1128278-g002.tif"/>
</fig>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Ferroptosis signatures. <bold>(A)</bold> Unsupervised clustering of overlapping ferroptosis-related genes in the TCGA-GBM cohorts to classify cases, termed as gene clusters A and B, respectively. The gene clusters, PCA scores, and age were applied as patient annotations. <bold>(B)</bold> KM curves of the gene clusters. <bold>(C)</bold> KM curves of the gene scores in the TCGA-GBM.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1128278-g003.tif"/>
</fig>
</sec>
<sec id="s3_4">
<title>Comparison of the immune activity</title>
<p>Based on the above analysis, this study used ssGSEA to compare the enrichment fraction of 16 types of immune cells and the activity difference of 13 immune-related pathways among groups in detail. The comparative analysis results show that in the TCGA queue (<xref ref-type="supplementary-material" rid="SM1">
<bold>Figures S2A, B</bold>
</xref>), the immune cell infiltration of the subgroup with high gene score is also higher, and the corresponding immune infiltration is mainly related to activated CD8<sup>+</sup>T, CD4<sup>+</sup>T, and Treg cells. The comparison results also showed that the infiltration of neutrophils and NK and Th cells in the high-score subgroup was more obvious.</p>
<p>Some immune pathways, such as the TGF beta pathway, NK cell-mediated cytotoxicity pathway, JAK&#x2013;STAT pathway, Toll-like receptor pathway, and B-cell receptor pathway, showed higher activity in the high-score group (<xref ref-type="supplementary-material" rid="SM1">
<bold>Figure S2C</bold>
</xref>). Moreover, amino sugar/nucleotide sugar/starch/sucrose metabolism and other glycan degradation pathways have higher activity in the high-gene score group, while taurine/hypotaurine-glycine/serine/threonine metabolism, calcium signaling, and neuroactive ligand&#x2013;receptor interactions have lower activity in the high-gene score group (<xref ref-type="supplementary-material" rid="SM1">
<bold>Figure S2D</bold>
</xref>). According to the comparative analysis results, the activity of the sucrose degradation pathway in the high-gene score group is significantly higher than that in the other group, but the corresponding calcium signaling and neural activity are relatively low (<xref ref-type="supplementary-material" rid="SM1">
<bold>Figure S2D</bold>
</xref>). The cause is not very clear, and it needs to be analyzed in detail to provide support for clarifying the pathological correlation between ferroptosis and this disease, so as to better meet the requirements related to treatment. Correlation analysis showed a significant positive correlation between immune cells in GBM, and almost all immune cells have a positive association with the PCA score and PCA gene score (<xref ref-type="fig" rid="f4">
<bold>Figures&#xa0;4A, B</bold>
</xref>).</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>The association of immune cells and PCA score <bold>(A)</bold> and PCA gene score <bold>(B)</bold>.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1128278-g004.tif"/>
</fig>
</sec>
<sec id="s3_5">
<title>Verification of potential biomarker expression</title>
<p>In order to further verify the role of the 25 differential genes we screened earlier in glioma, we detected the expression of the above genes in glioma glial tissue and glioma paracancerous glial tissue by immunohistochemistry, and the expression of the above genes in glioma glial tissue was significantly increased. Next, we detected four genes with differential expression greater than 10-fold by Western blot at the cellular and tissue levels, namely, <italic>MAP1LC3A</italic>, <italic>OLFM1</italic>, <italic>CEND1</italic>, and <italic>CLTB</italic>. The results showed that the expression levels of the above proteins were significantly upregulated relative to both glioma paracancerous glial cells and glioma paracancerous glial tissue. This further validates the results of our previous analysis (<xref ref-type="fig" rid="f5">
<bold>Figure 5</bold>
</xref>).</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>The expression of potential biomarkers. <bold>(A)</bold> Immunohistochemical detection of MAP1LC3A, OLFM1, CEND1, CLTB, PRKAR1B, HRAS, DDRGK1, PITHD1, and DEAF1 gene expression. <bold>(B)</bold> Western blot detection of the MAP1LC3A, OLFM1, CEND1, and CLTB protein expression levels. <bold>(C)</bold> Quantitative results of Western blotting. <bold>(D)</bold> Quantitative results of immunohistochemistry. *** means p value less than 0.001.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1128278-g005.tif"/>
</fig>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<title>Discussion</title>
<p>Malignant glioma is a fatal tumor, and many scholars found that ferroptosis is closely associated with glioma (<xref ref-type="bibr" rid="B31">31</xref>&#x2013;<xref ref-type="bibr" rid="B34">34</xref>). Ferroptosis is closely related to iron-mediated oxidative stress, cellular metabolism, and autophagy (<xref ref-type="bibr" rid="B35">35</xref>). Ferroptosis is very important in the development of glioma, while the related mechanism is still unclear. One study on the role and mechanism of ferroptosis in glioma can provide a better understanding of the pathogenesis of glioma and help to find new targets for the comprehensive treatment of glioma. Therefore, this study mainly aimed to identify DEGs associated with ferroptosis to offer a reliable theoretical basis for glioma therapy and construct a prognosis score for individual patients to better manage glioma treatment.</p>
<p>Ferroptosis inducers have high application value in tumor treatment (<xref ref-type="bibr" rid="B36">36</xref>). In cancer treatment, drug resistance is the key issue to be addressed. The comparative analysis showed that the process of cell death and apoptosis was significantly different in patients with iron deficiency syndrome. This drug can provide support in dealing with the drug resistance of tumors (<xref ref-type="bibr" rid="B37">37</xref>). Studies have found that activation of the ferroptosis pathway will promote the death of cancer cells, which can solve the problem of drug resistance, and also improve the sensitivity of cancer cells to drugs. The combined use of ferroptosis inducers and chemotherapy may achieve a synergistic reaction, thus improving sensitivity to chemotherapy. There is compelling evidence that glutathione peroxidase 4 inhibitors enhance the lethality of drug-resistant cells <italic>via</italic> ferroptosis which may help prevent acquired drug resistance in tumors (<xref ref-type="bibr" rid="B38">38</xref>). In addition, cisplatin in combination with erastin has been shown to significantly increase antitumor activity, suggesting that ferroptosis is critical in tumor therapy (<xref ref-type="bibr" rid="B39">39</xref>). It can improve the sensitivity of cancer cells to chemotherapy drugs, which is conducive to reducing the dosage and adverse drug reactions and is of great significance for improving the therapeutic effect. Autophagy inhibition in GBMs can enhance the sensitivity of GBM stem cells to treatment by causing ferroptosis (<xref ref-type="bibr" rid="B20">20</xref>). The combination of TMZ and erastin can provide effective therapy. Therefore, research on the treatment of ferroptosis may provide a new therapy approach for those who are resistant to traditional radiotherapy and chemotherapy or those who have not responded to immunotherapy.</p>
<p>In this study, we found that some ferroptosis genes could predict the OS of patients. Based on these genes, the PCA method was applied to determine the individual scores of patients and divide them into high- and low-score groups. Survival analysis reflected significant differences in OS between the two groups. Subsequently, 231 DEGs were identified between different score groups, and biological function analysis showed that these genes were mainly involved in the regulation of long-term neuronal synaptic plasticity, proteasome-mediated ubiquitin-dependent protein degradation, vesicle-mediated transport in synapses, proteasomal protein catabolic processes, etc. There were significant differences in immune activity between the two groups, suggesting that patients in the high-score group were in a state of immune activation. We further screened 231 DEGs for 25 prognostic DEGs and then used these genes for unsupervised classification. The OS rates were also compared and significant differences were found. In addition, the PCA algorithm was also applied to determine the PCA gene score of each patient, and cases were divided into high- and low-gene score groups. The survival analysis showed that the high-gene score group exhibited obviously a better prognosis. The high-gene score group had higher immune cell infiltration. Correlation analysis showed that the immune cells were positively associated with the PCA score and PCA gene score.</p>
<p>This study showed that GBM samples can be divided into two different groups using the PCA algorithm based on ferroptosis genes, and the low-score group has a worse prognosis. Subsequently, we identified 231 DEGs between different score groups, and 25 ferroptosis-related DEGs were identified based on Cox regression. The GBM samples were divided into two different clusters by an unsupervised clustering method. There were significant prognostic differences and immunoactivity between the two groups. In terms of the 25 prognostic DEGs, we further calculated individual risk scores using the PCA algorithm, which can be used to effectively predict the prognosis of a patient with glioma. Moreover, this research offers a novel understanding of the occurrence of ferroptosis in the progress of glioma and provides a valuable idea for the development of ferroptosis inducers for glioma therapy. Given that these partial results were generated using the public RNA-seq technique, further studies are needed to investigate the prognostic function of these 25 gene signatures.</p>
</sec>
<sec id="s5" sec-type="data-availability">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Material</bold>
</xref>. Further inquiries can be directed to the corresponding author.</p>
</sec>
<sec id="s6" sec-type="author-contributions">
<title>Author contributions</title>
<p>All authors designed the study, analyzed the data, and drafted the manuscript. All authors contributed to the article and approved the submitted version.</p>
</sec>
</body>
<back>
<sec id="s7" sec-type="funding-information">
<title>Funding</title>
<p>This study was supported by the 13th Chaoyang Talent Project of Guangdong Provincial Hospital of Traditional Chinese Medicine (ZY2022YL28), the Startup Fund from Guangzhou Municipal Science and Technology Bureau (No. 202002030221), the Science and Technology Innovation Guidance Project of Zhaoqing Municipal Science and Technology Bureau (No. 2021040308025), and the 17th Bajian Talent Project of Guangdong Provincial Hospital of Traditional Chinese Medicine (BJ2022YL06).</p>
</sec>
<sec id="s8" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s9" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s10" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fonc.2023.1128278/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fonc.2023.1128278/full#supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet_1.docx" id="SM1" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname> <given-names>T</given-names>
</name>
<name>
<surname>Nam</surname> <given-names>DH</given-names>
</name>
<name>
<surname>Ram</surname> <given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>Clinical practice guidelines for the management of adult diffuse gliomas</article-title>. <source>Cancer Lett</source> (<year>2021</year>) <volume>499</volume>:<fpage>60</fpage>&#x2013;<lpage>72</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.canlet.2020.10.050</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wesseling</surname> <given-names>P</given-names>
</name>
<name>
<surname>Capper</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>WHO 2016 classification of gliomas</article-title>. <source>Neuropathol Appl Neurobiol</source> (<year>2018</year>) <volume>44</volume>(<issue>2</issue>):<page-range>139&#x2013;50</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/nan.12432</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nayak</surname> <given-names>L</given-names>
</name>
<name>
<surname>Reardon</surname> <given-names>DA</given-names>
</name>
</person-group>. <article-title>High-grade gliomas</article-title>. <source>Continuum (Minneap Minn).</source> (<year>2017</year>) <volume>23</volume>(<issue>6, Neuro-oncology</issue>):<page-range>1548&#x2013;63</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1212/CON.0000000000000554</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zanders</surname> <given-names>ED</given-names>
</name>
<name>
<surname>Svensson</surname> <given-names>F</given-names>
</name>
<name>
<surname>Bailey</surname> <given-names>DS</given-names>
</name>
</person-group>. <article-title>Therapy for glioblastoma: is it working</article-title>? <source>Drug Discovery Today</source> (<year>2019</year>) <volume>24</volume>(<issue>5</issue>):<page-range>1193&#x2013;201</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.drudis.2019.03.008</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Picart</surname> <given-names>T</given-names>
</name>
<name>
<surname>Guyotat</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Glioblastome, des innovations en chirurgie [Glioblastoma, innovations in surgery]</article-title>. <source>Rev Infirm.</source> (<year>2017</year>) <volume>66</volume>(<issue>228</issue>):<page-range>31&#x2013;2</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.revinf.2016.12.008</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Campos</surname> <given-names>B</given-names>
</name>
<name>
<surname>Olsen</surname> <given-names>LR</given-names>
</name>
<name>
<surname>Urup</surname> <given-names>T</given-names>
</name>
<name>
<surname>Poulsen</surname> <given-names>HS</given-names>
</name>
</person-group>. <article-title>A comprehensive profile of recurrent glioblastoma</article-title>. <source>Oncogene.</source> (<year>2016</year>) <volume>35</volume>(<issue>45</issue>):<page-range>5819&#x2013;25</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/onc.2016.85</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hanahan</surname> <given-names>D</given-names>
</name>
<name>
<surname>Weinberg</surname> <given-names>RA</given-names>
</name>
</person-group>. <article-title>Hallmarks of cancer: the next generation</article-title>. <source>Cell.</source> (<year>2011</year>) <volume>144</volume>(<issue>5</issue>):<page-range>646&#x2013;74</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baudino</surname> <given-names>TA</given-names>
</name>
</person-group>. <article-title>Targeted cancer therapy: the next generation of cancer treatment</article-title>. <source>Curr Drug Discovery Technol</source> (<year>2015</year>) <volume>12</volume>(<issue>1</issue>):<fpage>3</fpage>&#x2013;<lpage>20</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.2174/1570163812666150602144310</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Palma</surname> <given-names>M</given-names>
</name>
<name>
<surname>Biziato</surname> <given-names>D</given-names>
</name>
<name>
<surname>Petrova</surname> <given-names>TV</given-names>
</name>
</person-group>. <article-title>Microenvironmental regulation of tumour angiogenesis</article-title>. <source>Nat Rev Cancer.</source> (<year>2017</year>) <volume>17</volume>(<issue>8</issue>):<page-range>457&#x2013;74</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nrc.2017.51</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arneth</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>Tumor microenvironment</article-title>. <source>Medicina (Kaunas).</source> (<year>2019</year>) <volume>56</volume>(<issue>1</issue>):<elocation-id>15</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/medicina56010015</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hinshaw</surname> <given-names>DC</given-names>
</name>
<name>
<surname>Shevde</surname> <given-names>LA</given-names>
</name>
</person-group>. <article-title>The tumor microenvironment innately modulates cancer progression</article-title>. <source>Cancer Res</source> (<year>2019</year>) <volume>79</volume>(<issue>18</issue>):<page-range>4557&#x2013;66</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-18-3962</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Broekman</surname> <given-names>ML</given-names>
</name>
<name>
<surname>Maas</surname> <given-names>SLN</given-names>
</name>
<name>
<surname>Abels</surname> <given-names>ER</given-names>
</name>
<name>
<surname>Mempel</surname> <given-names>TR</given-names>
</name>
<name>
<surname>Krichevsky</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Breakefield</surname> <given-names>XO</given-names>
</name>
</person-group>. <article-title>Multidimensional communication in the microenvirons of glioblastoma</article-title>. <source>Nat Rev Neurol</source> (<year>2018</year>) <volume>14</volume>(<issue>8</issue>):<page-range>482&#x2013;95</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41582-018-0025-8</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koren</surname> <given-names>E</given-names>
</name>
<name>
<surname>Fuchs</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>Modes of regulated cell death in cancer</article-title>. <source>Cancer Discovery</source> (<year>2021</year>) <volume>11</volume>(<issue>2</issue>):<page-range>245&#x2013;65</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1158/2159-8290.CD-20-0789</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stockwell</surname> <given-names>BR</given-names>
</name>
<name>
<surname>Friedmann Angeli</surname> <given-names>JP</given-names>
</name>
<name>
<surname>Bayir</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease</article-title>. <source>Cell.</source> (<year>2017</year>) <volume>171</volume>(<issue>2</issue>):<page-range>273&#x2013;85</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2017.09.021</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>X</given-names>
</name>
<name>
<surname>Li</surname> <given-names>J</given-names>
</name>
<name>
<surname>Kang</surname> <given-names>R</given-names>
</name>
<name>
<surname>Klionsky</surname> <given-names>DJ</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>Ferroptosis: machinery and regulation</article-title>. <source>Autophagy.</source> (<year>2021</year>) <volume>17</volume>(<issue>9</issue>):<page-range>2054&#x2013;81</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/15548627.2020.1810918</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Su</surname> <given-names>LJ</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>JH</given-names>
</name>
<name>
<surname>Gomez</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Reactive oxygen species-induced lipid peroxidation in apoptosis, autophagy, and ferroptosis</article-title>. <source>Oxid Med Cell Longev</source> (<year>2019</year>) <volume>2019</volume>:<elocation-id>5080843</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2019/5080843</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Imai</surname> <given-names>H</given-names>
</name>
<name>
<surname>Matsuoka</surname> <given-names>M</given-names>
</name>
<name>
<surname>Kumagai</surname> <given-names>T</given-names>
</name>
<name>
<surname>Sakamoto</surname> <given-names>T</given-names>
</name>
<name>
<surname>Koumura</surname> <given-names>T</given-names>
</name>
</person-group>. <article-title>Lipid peroxidation-dependent cell death regulated by GPx4 and ferroptosis</article-title>. <source>Curr Top Microbiol Immunol</source> (<year>2017</year>) <volume>403</volume>:<page-range>143&#x2013;70</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/82_2016_508</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Friedmann Angeli</surname> <given-names>JP</given-names>
</name>
<name>
<surname>Krysko</surname> <given-names>DV</given-names>
</name>
<name>
<surname>Conrad</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion</article-title>. <source>Nat Rev Cancer.</source> (<year>2019</year>) <volume>19</volume>(<issue>7</issue>):<page-range>405&#x2013;14</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41568-019-0149-1</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname> <given-names>L</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Fu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>C</given-names>
</name>
<name>
<surname>Tong</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Abnormally expressed ferroptosis-associated FANCD2 in mediating the temozolomide resistance and immune response in glioblastoma</article-title>. <source>Front Pharmacol</source> (<year>2022</year>) <volume>13</volume>:<elocation-id>921963</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fphar.2022.921963</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buccarelli</surname> <given-names>M</given-names>
</name>
<name>
<surname>Marconi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Pacioni</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Inhibition of autophagy increases susceptibility of glioblastoma stem cells to temozolomide by igniting ferroptosis</article-title>. <source>Cell Death Dis</source> (<year>2018</year>) <volume>9</volume>(<issue>8</issue>):<fpage>841</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41419-018-0864-7</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bowman</surname> <given-names>RL</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Carro</surname> <given-names>A</given-names>
</name>
<name>
<surname>Verhaak</surname> <given-names>RG</given-names>
</name>
<name>
<surname>Squatrito</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>GlioVis data portal for visualization and analysis of brain tumor expression datasets</article-title>. <source>Neuro Oncol</source> (<year>2017</year>) <volume>19</volume>(<issue>1</issue>):<page-range>139&#x2013;41</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/neuonc/now247</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname> <given-names>N</given-names>
</name>
<name>
<surname>Bao</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>FerrDb: a manually curated resource for regulators and markers of ferroptosis and ferroptosis-disease associations</article-title>. <source>Database (Oxford).</source> (<year>2020</year>) <volume>2020</volume>:<elocation-id>baaa021</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/database/baaa021</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ritchie</surname> <given-names>ME</given-names>
</name>
<name>
<surname>Phipson</surname> <given-names>B</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title>. <source>Nucleic Acids Res</source> (<year>2015</year>) <volume>43</volume>(<issue>7</issue>):<elocation-id>e47</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/nar/gkv007</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jafari</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ansari-Pour</surname> <given-names>N</given-names>
</name>
</person-group>. <article-title>Why, when and how to adjust your p values</article-title>? <source>Cell J</source> (<year>2019</year>) <volume>20</volume>(<issue>4</issue>):<page-range>604&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.22074/cellj.2019.5992</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilkerson</surname> <given-names>MD</given-names>
</name>
<name>
<surname>Hayes</surname> <given-names>DN</given-names>
</name>
</person-group>. <article-title>ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking</article-title>. <source>Bioinformatics.</source> (<year>2010</year>) <volume>26</volume>(<issue>12</issue>):<page-range>1572&#x2013;3</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/bioinformatics/btq170</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomas</surname> <given-names>PD</given-names>
</name>
</person-group>. <article-title>The gene ontology and the meaning of biological function</article-title>. <source>Methods Mol Biol</source> (<year>2017</year>) <volume>1446</volume>:<fpage>15</fpage>&#x2013;<lpage>24</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/978-1-4939-3743-1_2</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanehisa</surname> <given-names>M</given-names>
</name>
<name>
<surname>Furumichi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Tanabe</surname> <given-names>M</given-names>
</name>
<name>
<surname>Sato</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Morishima</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>KEGG: new perspectives on genomes, pathways, diseases and drugs</article-title>. <source>Nucleic Acids Res</source> (<year>2017</year>) <volume>45</volume>(<issue>D1</issue>):<page-range>D353&#x2013;61</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/nar/gkw1092</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname> <given-names>T</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>E</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>clusterProfiler 4.0: a universal enrichment tool for interpreting omics data</article-title>. <source>Innovation (Camb).</source> (<year>2021</year>) <volume>2</volume>(<issue>3</issue>):<elocation-id>100141</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.xinn.2021.100141</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>H&#xe4;nzelmann</surname> <given-names>S</given-names>
</name>
<name>
<surname>Castelo</surname> <given-names>R</given-names>
</name>
<name>
<surname>Guinney</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>GSVA: gene set variation analysis for microarray and RNA-seq data</article-title>. <source>BMC Bioinf</source> (<year>2013</year>) <volume>14</volume>:<elocation-id>7</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/1471-2105-14-7</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koletsi</surname> <given-names>D</given-names>
</name>
<name>
<surname>Pandis</surname> <given-names>N</given-names>
</name>
</person-group>. <article-title>Survival analysis, part 2: Kaplan-Meier method and the log-rank test</article-title>. <source>Am J Orthod Dentofacial Orthop</source> (<year>2017</year>) <volume>152</volume>(<issue>4</issue>):<page-range>569&#x2013;71</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ajodo.2017.07.008</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname> <given-names>J</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>YQ</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>BH</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>H</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>QX</given-names>
</name>
</person-group>. <article-title>ACSL4 suppresses glioma cells proliferation <italic>via</italic> activating ferroptosis</article-title>. <source>Oncol Rep</source> (<year>2020</year>) <volume>43</volume>(<issue>1</issue>):<page-range>147&#x2013;58</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3892/or.2019.7419</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wan</surname> <given-names>RJ</given-names>
</name>
<name>
<surname>Peng</surname> <given-names>W</given-names>
</name>
<name>
<surname>Xia</surname> <given-names>QX</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>HH</given-names>
</name>
<name>
<surname>Mao</surname> <given-names>XY</given-names>
</name>
</person-group>. <article-title>Ferroptosis-related gene signature predicts prognosis and immunotherapy in glioma</article-title>. <source>CNS Neurosci Ther</source> (<year>2021</year>) <volume>27</volume>(<issue>8</issue>):<page-range>973&#x2013;86</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/cns.13654</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhuo</surname> <given-names>S</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>Clinical and biological significances of a ferroptosis-related gene signature in glioma</article-title>. <source>Front Oncol</source> (<year>2020</year>) <volume>10</volume>:<elocation-id>590861</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fonc.2020.590861</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Mi</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Dihydroartemisinin-induced unfolded protein response feedback attenuates ferroptosis <italic>via</italic> PERK/ATF4/HSPA5 pathway in glioma cells</article-title>. <source>J Exp Clin Cancer Res</source> (<year>2019</year>) <volume>38</volume>(<issue>1</issue>):<fpage>402</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s13046-019-1413-7</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname> <given-names>E</given-names>
</name>
<name>
<surname>Chung</surname> <given-names>SW</given-names>
</name>
</person-group>. <article-title>ROS-mediated autophagy increases intracellular iron levels and ferroptosis by ferritin and transferrin receptor regulation</article-title>. <source>Cell Death Dis</source> (<year>2019</year>) <volume>10</volume>(<issue>11</issue>):<fpage>822</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41419-019-2064-5</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Dong</surname> <given-names>X</given-names>
</name>
</person-group>. <article-title>Recent progress in ferroptosis inducers for cancer therapy</article-title>. <source>Adv Mater</source> (<year>2019</year>) <volume>31</volume>(<issue>51</issue>):<elocation-id>e1904197</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/adma.201904197</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Jin</surname> <given-names>S</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>Ferroptosis in cancer therapy: a novel approach to reversing drug resistance</article-title>. <source>Mol Cancer.</source> (<year>2022</year>) <volume>21</volume>(<issue>1</issue>):<fpage>47</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12943-022-01530-y</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>You</surname> <given-names>JH</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>J</given-names>
</name>
<name>
<surname>Roh</surname> <given-names>JL</given-names>
</name>
</person-group>. <article-title>Mitochondrial pyruvate carrier 1 regulates ferroptosis in drug-tolerant persister head and neck cancer cells <italic>via</italic> epithelial-mesenchymal transition</article-title>. <source>Cancer Lett</source> (<year>2021</year>) <volume>507</volume>:<fpage>40</fpage>&#x2013;<lpage>54</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.canlet.2021.03.013</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Bao</surname> <given-names>L</given-names>
</name>
<name>
<surname>Li</surname> <given-names>M</given-names>
</name>
<name>
<surname>Chang</surname> <given-names>K</given-names>
</name>
<name>
<surname>Yi</surname> <given-names>X</given-names>
</name>
</person-group>. <article-title>Erastin synergizes with cisplatin <italic>via</italic> ferroptosis to inhibit ovarian cancer growth <italic>in vitro</italic> and <italic>in vivo</italic>
</article-title>. <source>J Obstet Gynaecol Res</source> (<year>2021</year>) <volume>47</volume>(<issue>7</issue>):<page-range>2481&#x2013;91</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/jog.14779</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>